{"protocolSection":{"identificationModule":{"nctId":"NCT06134804","orgStudyIdInfo":{"id":"CR109338"},"secondaryIdInfos":[{"id":"2023-504168-40-00","type":"REGISTRY","domain":"EUCT number"},{"id":"VAC52416BAC3002","type":"OTHER","domain":"Janssen Research & Development LLC"},{"id":"2023","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2023"}],"organization":{"fullName":"Janssen Research & Development, LLC","class":"INDUSTRY"},"briefTitle":"A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older","officialTitle":"A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older","acronym":"Engage"},"statusModule":{"statusVerifiedDate":"2026-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-10-24","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-02-19","type":"ACTUAL"},"completionDateStruct":{"date":"2024-07-26","type":"ACTUAL"},"studyFirstSubmitDate":"2023-11-13","studyFirstSubmitQcDate":"2023-11-13","studyFirstPostDateStruct":{"date":"2023-11-18","type":"ACTUAL"},"resultsFirstSubmitDate":"2026-02-10","resultsFirstSubmitQcDate":"2026-03-16","resultsFirstPostDateStruct":{"date":"2026-04-03","type":"ACTUAL"},"dispFirstSubmitDate":"2025-02-17","dispFirstPostDateStruct":{"date":"2026-04-03","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-03-16","lastUpdatePostDateStruct":{"date":"2026-04-03","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Janssen Research & Development, LLC","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to show that high-dose quadrivalent seasonal influenza vaccine (HD QIV) given together with 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) does not induce lower antibody response against each of the 4 influenza vaccine strains, as compared to HD QIV given alone and further show that ExPEC9V given together with HD QIV does not induce lower antibody response against each of the vaccine O-serotype antigens, as compared to ExPEC9V given alone."},"conditionsModule":{"conditions":["Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":959,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Group 1: Coadministration (CoAd) Group","type":"EXPERIMENTAL","description":"Participants will receive intramuscular (IM) injection of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) along with high-dose (HD) quadrivalent influenza vaccine, concomitantly, on Day 1 and placebo on Day 30.","interventionNames":["Biological: ExPEC9V","Biological: Placebo","Biological: HD quadrivalent influenza vaccine"]},{"label":"Group 2: Control Group","type":"EXPERIMENTAL","description":"Participants will receive IM injection of matching placebo along with HD quadrivalent influenza vaccine, concomitantly, on Day 1 and ExPEC9V on Day 30.","interventionNames":["Biological: ExPEC9V","Biological: Placebo","Biological: HD quadrivalent influenza vaccine"]}],"interventions":[{"type":"BIOLOGICAL","name":"ExPEC9V","description":"ExPEC9V will be administered as an IM injection.","armGroupLabels":["Group 1: Coadministration (CoAd) Group","Group 2: Control Group"],"otherNames":["VAC52416; JNJ-78901563"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Placebo will be administered as an IM injection.","armGroupLabels":["Group 1: Coadministration (CoAd) Group","Group 2: Control Group"]},{"type":"BIOLOGICAL","name":"HD quadrivalent influenza vaccine","description":"HD quadrivalent influenza vaccine will be administered as IM injection.","armGroupLabels":["Group 1: Coadministration (CoAd) Group","Group 2: Control Group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Hemagglutination Inhibition (HI) Antibody Titers Against H1N1, H3N2, B/Victoria, and B/Yamagata Influenza Vaccine Strains 29 Days After the Administration of High-Dose (HD) Quadrivalent Seasonal Influenza Vaccine","description":"HI antibody titers against H1N1, H3N2, B/Victoria, and B/Yamagata Influenza vaccine strains 29 days after the administration of HD quadrivalent seasonal influenza vaccine as measured by HI assay were reported.","timeFrame":"29 days after the administration of HD quadrivalent seasonal influenza vaccine on Day 1 (Day 30)"},{"measure":"Antibody Titers to Vaccine O-serotype Antigens as Determined by Multiplex Electrochemiluminescent (ECL)-Based Immunoassay 29 Days After Administration of ExPEC9V","description":"Antibody titers to vaccine O-serotype antigens (O1A, O2, O4, O6A, O15, O16, O18A, O25B, and O75) as determined by ECL based Immunoassay 29 days after administration of ExPEC9V on Day 1 in CoAd group and on Day 30 in Control group were reported.","timeFrame":"CoAd Group: 29 days after the administration of ExPEC9V on Day 1 (Day 30); Control Group: 29 days after the administration of ExPEC9V on Day 30 (Day 59)"}],"secondaryOutcomes":[{"measure":"Percentage of Participants With Seroconversion Against H1N1, H3N2, B/Victoria, and B/Yamagata Influenza Vaccine Strains 29 Days After the Administration of HD Quadrivalent Seasonal Influenza Vaccine","description":"Seroconversion was defined for each of the 4 influenza vaccine strains as 1) HI titer greater than or equal to (\\>=) 1:40 in participants with a pre-vaccination HI titer of less than (\\<) 1:10, or 2) a \\>=4-fold HI titer increase in participants with a pre-vaccination HI titer of \\>=1:10.","timeFrame":"29 days after the administration of HD quadrivalent seasonal influenza vaccine on Day 1 (Day 30)"},{"measure":"Percentage of Participants With Seroprotection Against H1N1, H3N2, B/Victoria, and B/Yamagata Influenza Vaccine Strains 29 Days After the Administration of HD Quadrivalent Seasonal Influenza Vaccine","description":"Seroprotection was defined for each of the 4 influenza vaccine strains as HI titer \\>=1:40 at 29 days after the administration of a HD quadrivalent seasonal influenza vaccine.","timeFrame":"29 days after the administration of HD quadrivalent seasonal influenza vaccine on Day 1 (Day 30)"},{"measure":"Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) for 14 Days After Each Vaccination","description":"An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccination. Solicited local AEs were used to assess the reactogenicity of the study vaccine and were pre-defined local (injection site) events for which participants were to be specifically questioned and which were noted by participants in their participant diary for 14 days post vaccination (day of vaccination and the subsequent 14 days). Solicited local AEs were injection site pain or tenderness, erythema and swelling at the study vaccine injection site.","timeFrame":"Up to 14 days post-vaccination 1 on Day 1 (Day 1 up to Day 15) and up to 14 days post-vaccination 2 on Day 30 (Day 30 up to Day 44)"},{"measure":"Percentage of Participants With Solicited Systemic AEs for 14 Days After Each Vaccination","description":"An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccination. Solicited systemic AEs were used to assess the reactogenicity of the study vaccine and were pre-defined systemic events for which participants were to be specifically questioned and which were noted by participants in their participant diary for 14 days post vaccination (day of vaccination and the subsequent 14 days). Solicited systemic AEs included fever (body temperature \\>=100.4 degree Fahrenheit), fatigue, headache, nausea, myalgia, and fever.","timeFrame":"Up to 14 days post-vaccination 1 on Day 1 (Day 1 up to Day 15) and up to 14 days post-vaccination 2 on Day 30 (Day 30 up to Day 44)"},{"measure":"Percentage of Participants With Unsolicited AEs for 29 Days After Each Vaccination","description":"Percentage of participants with unsolicited AEs for 29 days after each vaccination was reported. An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccination. Unsolicited AEs were all AEs for which the participant was not specifically questioned in the participant diary.","timeFrame":"Up to 29 days post-vaccination 1 on Day 1 (Day 1 up to Day 30) and up to 29 days post-vaccination 2 on Day 30 (Day 30 up to Day 59)"},{"measure":"Percentage of Participants With Medically-attended Adverse Events (MAAEs) From Vaccination 1 Until 6 Months After Vaccination 2","description":"MAAEs were defined as AEs with medically-attended visits including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason. An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccination.","timeFrame":"From vaccination 1 on Day 1 up to 6 months after vaccination 2 on Day 30 (up to Day 210)"},{"measure":"Percentage of Participants With Serious Adverse Events (SAEs) From Vaccination 1 Until 6 Months After Vaccination 2","description":"Percentage of participants with SAEs from vaccination 1 to until 6 months after vaccination 2 was reported. An AE was any untoward medical occurrence in a clinical study administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccine. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.","timeFrame":"From vaccination 1 on Day 1 up to 6 months after vaccination 2 on Day 30 (up to Day 210)"},{"measure":"Geometric Mean Titers of O-serotype Antigens and EPA as Determined by Multiplex ECL-based Immunoassay","description":"Antibody titers to vaccine O-serotype antigens (O1A, O2, O4, O6A, O15, O16, O18A, O25B, and O75) and EPA as determined by multiplex ECL-based immunoassay were reported.","timeFrame":"CoAd Group: Day 1 (Day of ExPEC9V vaccination), Day 30 (29 days after ExPEC9V vaccination), Day 59 (58 days after ExPEC9V vaccination); Control Group: Day 30 (Day of ExPEC9V vaccination), Day 59 (29 days after ExPEC9V vaccination)"},{"measure":"CoAd Group: Opsonophagocytic Geometric Mean Titers of O-serotype Antigens as Determined by Multiplex Opsonophagocytic Killing Assay (MOPA)","description":"Opsonophagocytic antibody titers to vaccine O-serotype antigens O1A, O2, O4, O6A, O15, O16, O18A, O25B, and O75 as determined by MOPA were reported.","timeFrame":"29 days after the administration of ExPEC9V vaccine on Day 1 (Day 30)"},{"measure":"Control Group: Opsonophagocytic Geometric Mean Titers of O-serotype Antigens as Determined by Multiplex Opsonophagocytic Killing Assay (MOPA)","description":"Opsonophagocytic antibody titers to vaccine O-serotype antigens (O1A, O2, O4, O6A, O15, O16, O18A, O25B, and O75) as determined by MOPA were reported.","timeFrame":"29 days after the administration of ExPEC9V vaccine on Day 30 (Day 59)"},{"measure":"CoAd Group: Antibody Titers to Vaccine O-serotype Antigens in Participants With and Without History of Urinary Tract Infection (UTI) at Enrollment as Determined by Multiplex ECL-based Immunoassay","description":"Antibody titers to vaccine O-serotype antigens (O1A, O2, O4, O6A, O15, O16, O18A, O25B, and O75) in participants with and without history of UTI at enrollment as determined by multiplex ECL-based immunoassay were reported.","timeFrame":"29 days after the administration of ExPEC9V on Day 1 (Day 30)"},{"measure":"Control Group: Antibody Titers to Vaccine O-serotype Antigens in Participants With and Without History of UTI at Enrollment as Determined by Multiplex ECL-based Immunoassay","description":"Antibody titers to vaccine O-serotype antigens (O1A, O2, O4, O6A, O15, O16, O18A, O25B, and O75) in participants with and without history of UTI at enrollment as determined by multiplex ECL-based immunoassay were reported.","timeFrame":"29 days after the administration of ExPEC9V on Day 30 (Day 59)"},{"measure":"CoAd Group: Opsonophagocytic Antibody Titers to Vaccine O-serotype Antigens in Participants With and Without History of UTI at Enrollment as Determined by Multiplex Opsonophagocytic Killing Assay (MOPA)","description":"Opsonophagocytic antibody titers to vaccine O-serotype antigens (O1A, O2, O4, O6A, O15, O16, O18A, O25B, and O75) in participants with and without history of UTI at enrollment as determined by MOPA were reported.","timeFrame":"29 days after the administration of ExPEC9V on Day 1 (Day 30)"},{"measure":"Control Group: Opsonophagocytic Antibody Titers to Vaccine O-serotype Antigens in Participants With and Without History of UTI at Enrollment as Determined by Multiplex Opsonophagocytic Killing Assay (MOPA)","description":"Opsonophagocytic antibody titers to vaccine O-serotype antigens (O1A, O2, O4, O6A, O15, O16, O18A, O25B, and O75) in participants with and without history of UTI at enrollment as determined by MOPA were reported.","timeFrame":"29 days after the administration of ExPEC9V on Day 30 (Day 59)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must be medically stable at the time of vaccination such that, according to the judgment of the investigator, hospitalization within the study period is not anticipated and the participant appears likely to be able to remain on study through the end of protocol specified follow-up. A stable medical condition is defined as disease not requiring significant change in therapy during the 6 weeks before enrollment and when hospitalization for worsening of the disease is not anticipated. Participants will be included on the basis of physical examination, medical history, and vital signs performed between informed consent form (ICF) signature and vaccination\n* Participant must be: a) postmenopausal (postmenopausal state is defined as no menses for 12 months without an alternative medical cause); and b) not intending to conceive by any methods\n* Must sign an ICF indicating that the participant understands the purpose, procedures and potential risks and benefits of the study, and is willing to participate in the study\n* Willing and able to adhere to the lifestyle restrictions specified in this protocol\n* Agrees to not donate blood from the time of vaccination until 3 months after receiving the last dose of study vaccine\n\nExclusion Criteria:\n\n* History of an underlying clinically significant acute or uncontrolled chronic medical condition or significant cognitive impairment or physical examination findings for which, in the opinion of the investigator, participation would not be in the best interest of the participant (for example, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments\n* Known or suspected allergy or history of severe allergic reaction, anaphylaxis, or other serious adverse reactions to vaccines or vaccine excipients\n* History of severe allergic reactions (for example anaphylaxis) to any component of the high-dose (HD) quadrivalent seasonal influenza vaccine, including egg protein, or following a previous dose of any influenza vaccine\n* Has had major surgery (per the investigator's judgment) within 4 weeks before administration of the first study vaccine or will not have recovered from surgery per the investigator's judgment at time of vaccination\n* History of acute polyneuropathy (for example, Guillain-Barré syndrome) or chronic inflammatory demyelinating polyneuropathy","healthyVolunteers":true,"sex":"ALL","minimumAge":"65 Years","stdAges":["OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Janssen Research & Development LLC Clinical Trial","affiliation":"Janssen Research & Development, LLC","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Medical Affiliated Research Center Inc. (MARC)","city":"Huntsville","state":"Alabama","zip":"35801","country":"United States","geoPoint":{"lat":34.7304,"lon":-86.58594}},{"facility":"Alliance for Multispeciality Research","city":"Mobile","state":"Alabama","zip":"36608","country":"United States","geoPoint":{"lat":30.69436,"lon":-88.04305}},{"facility":"Artemis Institute for Clinical Research","city":"San Diego","state":"California","zip":"92103","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Diablo Clinical Research, Inc.","city":"Walnut Creek","state":"California","zip":"94598","country":"United States","geoPoint":{"lat":37.90631,"lon":-122.06496}},{"facility":"Optimal Research","city":"Melbourne","state":"Florida","zip":"32934","country":"United States","geoPoint":{"lat":28.08363,"lon":-80.60811}},{"facility":"Pharmax Research Clinic Inc","city":"Miami","state":"Florida","zip":"33126","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Suncoast Research Associates, LLC","city":"Miami","state":"Florida","zip":"33173","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Atlanta Center for Medical Research","city":"Atlanta","state":"Georgia","zip":"30331","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Velocity Clinical Research","city":"Savannah","state":"Georgia","zip":"31406","country":"United States","geoPoint":{"lat":32.08354,"lon":-81.09983}},{"facility":"Synexus Clinical Research US Inc","city":"Chicago","state":"Illinois","zip":"60602","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Optimal Research","city":"Peoria","state":"Illinois","zip":"61614","country":"United States","geoPoint":{"lat":40.69365,"lon":-89.58899}},{"facility":"Synexus Radiant Research, Inc","city":"Evansville","state":"Indiana","zip":"47714","country":"United States","geoPoint":{"lat":37.97476,"lon":-87.55585}},{"facility":"Heartland Research Associates, LLC","city":"Newton","state":"Kansas","zip":"67114","country":"United States","geoPoint":{"lat":38.04668,"lon":-97.34504}},{"facility":"Heartland Research Associates, an AMR Company","city":"Wichita","state":"Kansas","zip":"67207","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"Alliance for Multispeciality Research","city":"Lexington","state":"Kentucky","zip":"40509","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"Synexus Clinical Research US Inc","city":"Creve Coeur","state":"Missouri","zip":"63141","country":"United States","geoPoint":{"lat":38.66089,"lon":-90.42262}},{"facility":"Accellacare","city":"Wilmington","state":"North Carolina","zip":"28401","country":"United States","geoPoint":{"lat":34.23556,"lon":-77.94604}},{"facility":"CTI Clinical Trial and Consulting Services","city":"Cincinnati","state":"Ohio","zip":"45212","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Velocity Clinical Research","city":"Cleveland","state":"Ohio","zip":"44122","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Velocity Clinical Research","city":"East Greenwich","state":"Rhode Island","zip":"02818","country":"United States","geoPoint":{"lat":41.66038,"lon":-71.45589}},{"facility":"Alliance for Multispeciality Research","city":"Knoxville","state":"Tennessee","zip":"37909","country":"United States","geoPoint":{"lat":35.96064,"lon":-83.92074}},{"facility":"Benchmark Clinical Research - Austin","city":"Austin","state":"Texas","zip":"78705","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Optimal Research","city":"Austin","state":"Texas","zip":"78744","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Tekton Research Inc.","city":"Beaumont","state":"Texas","zip":"77706","country":"United States","geoPoint":{"lat":30.08605,"lon":-94.10185}},{"facility":"Universiteit Antwerpen - Centrum voor de Evaluatie van Vaccinaties (CEV)","city":"Edegem","zip":"2650","country":"Belgium","geoPoint":{"lat":51.15662,"lon":4.44504}},{"facility":"Center for Vaccinology (CEVAC)","city":"Ghent","zip":"9000","country":"Belgium","geoPoint":{"lat":51.05,"lon":3.71667}},{"facility":"Az Sint-Maarten","city":"Mechelen","zip":"2800","country":"Belgium","geoPoint":{"lat":51.02574,"lon":4.47762}},{"facility":"Aggarwal and associates Ltd","city":"Brampton","state":"Ontario","zip":"L6T 0G1","country":"Canada","geoPoint":{"lat":43.68341,"lon":-79.76633}},{"facility":"Milestone Research","city":"London","state":"Ontario","zip":"N5W 6A2","country":"Canada","geoPoint":{"lat":42.98339,"lon":-81.23304}},{"facility":"Centricity Research- Manna Research (MR) - Quebec Location","city":"Lévis","state":"Quebec","zip":"G6W 0M5","country":"Canada","geoPoint":{"lat":46.80326,"lon":-71.17793}},{"facility":"Synexus Polska Sp. z o.o. Oddzial w Gdansku","city":"Gdansk","zip":"80 382","country":"Poland","geoPoint":{"lat":54.35227,"lon":18.64912}},{"facility":"PUNKT ZDROWIA Hlebowicz Jakubowski Lekarze sp.p.","city":"Gdansk","zip":"80405","country":"Poland","geoPoint":{"lat":54.35227,"lon":18.64912}},{"facility":"Synexus Polska Sp. z o.o. Oddzial w Gdynia","city":"Gdynia","zip":"81 537","country":"Poland","geoPoint":{"lat":54.51889,"lon":18.53188}},{"facility":"Synexus Polska Sp z o o Oddzial w Katowicach","city":"Katowice","zip":"40 040","country":"Poland","geoPoint":{"lat":50.2597,"lon":19.02173}},{"facility":"Pratia MCM Krakow","city":"Krakow","zip":"30 727","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Velocity Lublin","city":"Lublin","zip":"20 362","country":"Poland","geoPoint":{"lat":51.25058,"lon":22.57009}},{"facility":"Velocity Staszow","city":"Staszów","zip":"28 200","country":"Poland","geoPoint":{"lat":50.56307,"lon":21.16593}},{"facility":"MICS Centrum Medyczne Torun","city":"Torun","zip":"87-100","country":"Poland","geoPoint":{"lat":53.01375,"lon":18.59814}},{"facility":"MICS Centrum Medyczne Warszawa","city":"Warsaw","zip":"00 874","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Synexus Polska Sp z o o Oddzial w Warszawie","city":"Warsaw","zip":"02 672","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Synexus Polska Sp z o o Oddzial we Wroclawiu","city":"Wroclaw","zip":"50 381","country":"Poland","geoPoint":{"lat":51.10286,"lon":17.03006}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \\& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu","url":"https://www.janssen.com/clinical-trials/transparency"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"CoAd","description":"Participants received a single blinded intramuscular injection of 176 micrograms (mcg) polysaccharide per milliliter (PS/mL) ExPEC9V vaccine in one arm and an unblinded High-dose (HD) quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by a blinded placebo matching the ExPEC9V vaccine on Day 30 in Coadministration (CoAd) group."},{"id":"FG001","title":"Control","description":"Participants received a single blinded intramuscular injection of placebo matching the ExPEC9V vaccine in one arm and an unblinded HD quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by blinded single intramuscular injection of 176 mcg PS/mL ExPEC9V vaccine on Day 30."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"477"},{"groupId":"FG001","numSubjects":"482"}]},{"type":"Treated","achievements":[{"groupId":"FG000","numSubjects":"476"},{"groupId":"FG001","numSubjects":"481"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"455"},{"groupId":"FG001","numSubjects":"460"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"22"}]}],"dropWithdraws":[{"type":"Initiated Prohibited Medication","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Withdrawal of Consent","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"12"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Protocol Deviation","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Randomized not Treated","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"The Full analysis set (FAS) included all participants who received at least 1 study vaccination, regardless of the occurrence of protocol deviations and vaccine type (influenza vaccine, ExPEC9V, or placebo).","groups":[{"id":"BG000","title":"CoAd","description":"Participants received a single blinded intramuscular injection of 176 micrograms (mcg) polysaccharide per milliliter (PS/mL) ExPEC9V vaccine in one arm and an unblinded High-Dose (HD) quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by a blinded placebo matching the ExPEC9V vaccine on Day 30 in Coadministration (CoAd) group."},{"id":"BG001","title":"Control","description":"Participants received a single blinded intramuscular injection of placebo matching the ExPEC9V vaccine in one arm and an unblinded HD quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by blinded single intramuscular injection of 176 mcg PS/mL ExPEC9V vaccine on Day 30."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"476"},{"groupId":"BG001","value":"481"},{"groupId":"BG002","value":"957"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"71.5","spread":"5.08"},{"groupId":"BG001","value":"71.8","spread":"4.89"},{"groupId":"BG002","value":"71.6","spread":"4.99"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"265"},{"groupId":"BG001","value":"264"},{"groupId":"BG002","value":"529"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"211"},{"groupId":"BG001","value":"217"},{"groupId":"BG002","value":"428"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"61"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"441"},{"groupId":"BG001","value":"451"},{"groupId":"BG002","value":"892"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"22"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"58"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"438"},{"groupId":"BG001","value":"430"},{"groupId":"BG002","value":"868"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Hemagglutination Inhibition (HI) Antibody Titers Against H1N1, H3N2, B/Victoria, and B/Yamagata Influenza Vaccine Strains 29 Days After the Administration of High-Dose (HD) Quadrivalent Seasonal Influenza Vaccine","description":"HI antibody titers against H1N1, H3N2, B/Victoria, and B/Yamagata Influenza vaccine strains 29 days after the administration of HD quadrivalent seasonal influenza vaccine as measured by HI assay were reported.","populationDescription":"Per protocol influenza immunogenicity (PPII) analysis set included all randomized participants who received first study vaccination (ExPEC9V in combination with HD quadrivalent seasonal influenza vaccine for CoAd group and HD quadrivalent seasonal influenza vaccine alone for the Control group) for whom immunogenicity data were available for at least 1 of the influenza strains in vaccine. N (Overall number of participants analyzed) signifies participants evaluable for this outcome measure (OM).","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"29 days after the administration of HD quadrivalent seasonal influenza vaccine on Day 1 (Day 30)","groups":[{"id":"OG000","title":"CoAd","description":"Participants received a single blinded intramuscular injection of 176 micrograms (mcg) polysaccharide per milliliter (PS/mL) ExPEC9V vaccine in one arm and an unblinded High-dose (HD) quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by a blinded placebo matching the ExPEC9V vaccine on Day 30 in Coadministration (CoAd) group."},{"id":"OG001","title":"Control","description":"Participants received a single blinded intramuscular injection of placebo matching the ExPEC9V vaccine in one arm and an unblinded HD quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by blinded single intramuscular injection of 176 mcg PS/mL ExPEC9V vaccine on Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"448"},{"groupId":"OG001","value":"453"}]}],"classes":[{"title":"H1N1","categories":[{"measurements":[{"groupId":"OG000","value":"368.94","lowerLimit":"321.31","upperLimit":"423.62"},{"groupId":"OG001","value":"362.43","lowerLimit":"316.39","upperLimit":"415.16"}]}]},{"title":"H3N2","categories":[{"measurements":[{"groupId":"OG000","value":"328.38","lowerLimit":"280.72","upperLimit":"384.13"},{"groupId":"OG001","value":"335.91","lowerLimit":"287.93","upperLimit":"391.89"}]}]},{"title":"B/Victoria","categories":[{"measurements":[{"groupId":"OG000","value":"727.27","lowerLimit":"647.29","upperLimit":"817.12"},{"groupId":"OG001","value":"703.30","lowerLimit":"627.21","upperLimit":"788.62"}]}]},{"title":"B/Yamagata","categories":[{"measurements":[{"groupId":"OG000","value":"638.64","lowerLimit":"572.77","upperLimit":"712.07"},{"groupId":"OG001","value":"572.60","lowerLimit":"514.50","upperLimit":"637.26"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"H1N1","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Non-inferiority margin was 1.5 for the ratio of the geometric mean of the Control group over the geometric mean of the CoAd group.","paramType":"Geometric Mean Ratio (Control/CoAd)","paramValue":"0.982","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.832","ciUpperLimit":"1.160"},{"groupIds":["OG000","OG001"],"groupDescription":"H3N2","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Non-inferiority margin was 1.5 for the ratio of the geometric mean of the Control group over the geometric mean of the CoAd group.","paramType":"Geometric Mean Ratio (Control/CoAd)","paramValue":"1.023","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.847","ciUpperLimit":"1.235"},{"groupIds":["OG000","OG001"],"groupDescription":"B/Victoria","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Non-inferiority margin was 1.5 for the ratio of the geometric mean of the Control group over the geometric mean of the CoAd group.","paramType":"Geometric Mean Ratio (Control/CoAd)","paramValue":"0.967","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.841","ciUpperLimit":"1.113"},{"groupIds":["OG000","OG001"],"groupDescription":"B/Yamagata","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Non-inferiority margin was 1.5 for the ratio of the geometric mean of the Control group over the geometric mean of the CoAd group.","paramType":"Geometric Mean Ratio (Control/CoAd)","paramValue":"0.897","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.787","ciUpperLimit":"1.022"}]},{"type":"PRIMARY","title":"Antibody Titers to Vaccine O-serotype Antigens as Determined by Multiplex Electrochemiluminescent (ECL)-Based Immunoassay 29 Days After Administration of ExPEC9V","description":"Antibody titers to vaccine O-serotype antigens (O1A, O2, O4, O6A, O15, O16, O18A, O25B, and O75) as determined by ECL based Immunoassay 29 days after administration of ExPEC9V on Day 1 in CoAd group and on Day 30 in Control group were reported.","populationDescription":"Per protocol ExPEC immunogenicity (PPEI) analysis set included all randomized participants who received ExPEC9V in combination with a HD quadrivalent seasonal influenza vaccine for the CoAd group and ExPEC9V alone for the control group and for whom O-antigen immunogenicity data were available for at least one E. coli serotype.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"CoAd Group: 29 days after the administration of ExPEC9V on Day 1 (Day 30); Control Group: 29 days after the administration of ExPEC9V on Day 30 (Day 59)","groups":[{"id":"OG000","title":"CoAd","description":"Participants received a single blinded intramuscular injection of 176 micrograms (mcg) polysaccharide per milliliter (PS/mL) ExPEC9V vaccine in one arm and an unblinded High-dose (HD) quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by a blinded placebo matching the ExPEC9V vaccine on Day 30 in Coadministration (CoAd) group."},{"id":"OG001","title":"Control","description":"Participants received a single blinded intramuscular injection of placebo matching the ExPEC9V vaccine in one arm and an unblinded HD quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by blinded single intramuscular injection of 176 mcg PS/mL ExPEC9V vaccine on Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"448"},{"groupId":"OG001","value":"442"}]}],"classes":[{"title":"O1A serotype","categories":[{"measurements":[{"groupId":"OG000","value":"5346351.53","lowerLimit":"4590112.96","upperLimit":"6227183.28"},{"groupId":"OG001","value":"7269565.30","lowerLimit":"6248177.53","upperLimit":"8457919.04"}]}]},{"title":"O2 serotype","categories":[{"measurements":[{"groupId":"OG000","value":"2452599.76","lowerLimit":"2080377.11","upperLimit":"2891420.77"},{"groupId":"OG001","value":"3865399.96","lowerLimit":"3282667.19","upperLimit":"4551578.33"}]}]},{"title":"O4 serotype","categories":[{"measurements":[{"groupId":"OG000","value":"5584467.27","lowerLimit":"4877747.63","upperLimit":"6393581.02"},{"groupId":"OG001","value":"7110481.05","lowerLimit":"6216723.83","upperLimit":"8132730.69"}]}]},{"title":"O6A serotype","categories":[{"measurements":[{"groupId":"OG000","value":"7337171.91","lowerLimit":"6439792.25","upperLimit":"8359600.66"},{"groupId":"OG001","value":"10104308.16","lowerLimit":"8876863.29","upperLimit":"11501477.51"}]}]},{"title":"O15 serotype","categories":[{"measurements":[{"groupId":"OG000","value":"3702737.22","lowerLimit":"3222088.49","upperLimit":"4255085.77"},{"groupId":"OG001","value":"4799596.43","lowerLimit":"4180767.80","upperLimit":"5510022.79"}]}]},{"title":"O16 serotype","categories":[{"measurements":[{"groupId":"OG000","value":"5874788.10","lowerLimit":"5082969.87","upperLimit":"6789954.72"},{"groupId":"OG001","value":"7715064.34","lowerLimit":"6682202.59","upperLimit":"8907574.55"}]}]},{"title":"O18A serotype","categories":[{"measurements":[{"groupId":"OG000","value":"22297849.38","lowerLimit":"19548964.41","upperLimit":"25433269.85"},{"groupId":"OG001","value":"28863213.00","lowerLimit":"25329039.85","upperLimit":"32890511.03"}]}]},{"title":"O25B serotype","categories":[{"measurements":[{"groupId":"OG000","value":"12264386.02","lowerLimit":"10440594.11","upperLimit":"14406762.95"},{"groupId":"OG001","value":"18321682.05","lowerLimit":"15615304.68","upperLimit":"21497117.08"}]}]},{"title":"O75 serotype","categories":[{"measurements":[{"groupId":"OG000","value":"10831355.27","lowerLimit":"9499949.54","upperLimit":"12349355.79"},{"groupId":"OG001","value":"12424865.47","lowerLimit":"10907925.98","upperLimit":"14152762.16"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"O1A serotype","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Non-inferiority margin was 1.5 for the ratio of the geometric mean of the Control group over the geometric mean of the CoAd group.","paramType":"Geometric Mean Ratio (Control/CoAd)","paramValue":"1.36","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.130","ciUpperLimit":"1.635"},{"groupIds":["OG000","OG001"],"groupDescription":"O2 serotype","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Non-inferiority margin was 1.5 for the ratio of the geometric mean of the Control group over the geometric mean of the CoAd group.","paramType":"Geometric Mean Ratio (Control/CoAd)","paramValue":"1.576","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.291","ciUpperLimit":"1.924"},{"groupIds":["OG000","OG001"],"groupDescription":"O4 serotype","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Non-inferiority margin was 1.5 for the ratio of the geometric mean of the Control group over the geometric mean of the CoAd group.","paramType":"Geometric Mean Ratio (Control/CoAd)","paramValue":"1.273","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.081","ciUpperLimit":"1.500"},{"groupIds":["OG000","OG001"],"groupDescription":"O6A serotype","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Non-inferiority margin was 1.5 for the ratio of the geometric mean of the Control group over the geometric mean of the CoAd group.","paramType":"Geometric Mean Ratio (Control/CoAd)","paramValue":"1.377","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.176","ciUpperLimit":"1.613"},{"groupIds":["OG000","OG001"],"groupDescription":"O15 serotype","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Non-inferiority margin was 1.5 for the ratio of the geometric mean of the Control group over the geometric mean of the CoAd group.","paramType":"Geometric Mean Ratio (Control/CoAd)","paramValue":"1.296","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.095","ciUpperLimit":"1.534"},{"groupIds":["OG000","OG001"],"groupDescription":"O16 serotype","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Non-inferiority margin was 1.5 for the ratio of the geometric mean of the Control group over the geometric mean of the CoAd group.","paramType":"Geometric Mean Ratio (Control/CoAd)","paramValue":"1.313","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.102","ciUpperLimit":"1.565"},{"groupIds":["OG000","OG001"],"groupDescription":"O18A serotype","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Non-inferiority margin was 1.5 for the ratio of the geometric mean of the Control group over the geometric mean of the CoAd group.","paramType":"Geometric Mean Ratio (Control/CoAd)","paramValue":"1.294","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.104","ciUpperLimit":"1.518"},{"groupIds":["OG000","OG001"],"groupDescription":"O25B serotype","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Non-inferiority margin was 1.5 for the ratio of the geometric mean of the Control group over the geometric mean of the CoAd group.","paramType":"Geometric Mean Ratio (Control/CoAd)","paramValue":"1.494","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.229","ciUpperLimit":"1.815"},{"groupIds":["OG000","OG001"],"groupDescription":"O75 serotype","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Non-inferiority margin was 1.5 for the ratio of the geometric mean of the Control group over the geometric mean of the CoAd group.","paramType":"Geometric Mean Ratio (Control/CoAd)","paramValue":"1.147","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.979","ciUpperLimit":"1.345"}]},{"type":"SECONDARY","title":"Percentage of Participants With Seroconversion Against H1N1, H3N2, B/Victoria, and B/Yamagata Influenza Vaccine Strains 29 Days After the Administration of HD Quadrivalent Seasonal Influenza Vaccine","description":"Seroconversion was defined for each of the 4 influenza vaccine strains as 1) HI titer greater than or equal to (\\>=) 1:40 in participants with a pre-vaccination HI titer of less than (\\<) 1:10, or 2) a \\>=4-fold HI titer increase in participants with a pre-vaccination HI titer of \\>=1:10.","populationDescription":"PPII analysis set included all randomized participants who received first study vaccination (ExPEC9V in combination with HD quadrivalent seasonal influenza vaccine for CoAd group and HD quadrivalent seasonal influenza vaccine alone for Control group) and for whom immunogenicity data were available for at least 1 of the influenza strains in vaccine. Here, N (Overall number of participants analyzed) signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"29 days after the administration of HD quadrivalent seasonal influenza vaccine on Day 1 (Day 30)","groups":[{"id":"OG000","title":"CoAd","description":"Participants received a single blinded intramuscular injection of 176 micrograms (mcg) polysaccharide per milliliter (PS/mL) ExPEC9V vaccine in one arm and an unblinded High-dose (HD) quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by a blinded placebo matching the ExPEC9V vaccine on Day 30 in Coadministration (CoAd) group."},{"id":"OG001","title":"Control","description":"Participants received a single blinded intramuscular injection of placebo matching the ExPEC9V vaccine in one arm and an unblinded HD quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by blinded single intramuscular injection of 176 mcg PS/mL ExPEC9V vaccine on Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"448"},{"groupId":"OG001","value":"453"}]}],"classes":[{"title":"H1N1","categories":[{"measurements":[{"groupId":"OG000","value":"76.1","lowerLimit":"72.0","upperLimit":"79.9"},{"groupId":"OG001","value":"74.4","lowerLimit":"70.2","upperLimit":"78.3"}]}]},{"title":"H3N2","categories":[{"measurements":[{"groupId":"OG000","value":"79.9","lowerLimit":"76.0","upperLimit":"83.4"},{"groupId":"OG001","value":"73.1","lowerLimit":"68.8","upperLimit":"77.0"}]}]},{"title":"B/Victoria","categories":[{"measurements":[{"groupId":"OG000","value":"71.7","lowerLimit":"67.3","upperLimit":"75.7"},{"groupId":"OG001","value":"65.6","lowerLimit":"61.1","upperLimit":"69.8"}]}]},{"title":"B/Yamagata","categories":[{"measurements":[{"groupId":"OG000","value":"56.9","lowerLimit":"52.3","upperLimit":"61.5"},{"groupId":"OG001","value":"52.3","lowerLimit":"47.7","upperLimit":"56.9"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Seroprotection Against H1N1, H3N2, B/Victoria, and B/Yamagata Influenza Vaccine Strains 29 Days After the Administration of HD Quadrivalent Seasonal Influenza Vaccine","description":"Seroprotection was defined for each of the 4 influenza vaccine strains as HI titer \\>=1:40 at 29 days after the administration of a HD quadrivalent seasonal influenza vaccine.","populationDescription":"PPII analysis set included all randomized participants who received first study vaccination (ExPEC9V in combination with HD quadrivalent seasonal influenza vaccine for CoAd group and HD quadrivalent seasonal influenza vaccine alone for Control group) and for whom immunogenicity data were available for at least 1 of the influenza strains in vaccine. Here, N (Overall number of participants analyzed) signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"29 days after the administration of HD quadrivalent seasonal influenza vaccine on Day 1 (Day 30)","groups":[{"id":"OG000","title":"CoAd","description":"Participants received a single blinded intramuscular injection of 176 micrograms (mcg) polysaccharide per milliliter (PS/mL) ExPEC9V vaccine in one arm and an unblinded High-dose (HD) quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by a blinded placebo matching the ExPEC9V vaccine on Day 30 in Coadministration (CoAd) group."},{"id":"OG001","title":"Control","description":"Participants received a single blinded intramuscular injection of placebo matching the ExPEC9V vaccine in one arm and an unblinded HD quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by blinded single intramuscular injection of 176 mcg PS/mL ExPEC9V vaccine on Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"448"},{"groupId":"OG001","value":"453"}]}],"classes":[{"title":"H1N1","categories":[{"measurements":[{"groupId":"OG000","value":"93.1","lowerLimit":"90.4","upperLimit":"95.2"},{"groupId":"OG001","value":"93.4","lowerLimit":"90.8","upperLimit":"95.4"}]}]},{"title":"H3N2","categories":[{"measurements":[{"groupId":"OG000","value":"88.6","lowerLimit":"85.4","upperLimit":"91.3"},{"groupId":"OG001","value":"89.6","lowerLimit":"86.6","upperLimit":"92.2"}]}]},{"title":"B/Victoria","categories":[{"measurements":[{"groupId":"OG000","value":"98.0","lowerLimit":"96.3","upperLimit":"99.0"},{"groupId":"OG001","value":"99.6","lowerLimit":"98.5","upperLimit":"99.9"}]}]},{"title":"B/Yamagata","categories":[{"measurements":[{"groupId":"OG000","value":"98.7","lowerLimit":"97.2","upperLimit":"99.5"},{"groupId":"OG001","value":"99.6","lowerLimit":"98.5","upperLimit":"99.9"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) for 14 Days After Each Vaccination","description":"An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccination. Solicited local AEs were used to assess the reactogenicity of the study vaccine and were pre-defined local (injection site) events for which participants were to be specifically questioned and which were noted by participants in their participant diary for 14 days post vaccination (day of vaccination and the subsequent 14 days). Solicited local AEs were injection site pain or tenderness, erythema and swelling at the study vaccine injection site.","populationDescription":"FAS included all participants who received at least one study vaccination, regardless of the occurrence of protocol deviations and vaccine type (HD quadrivalent seasonal influenza vaccine, ExPEC9V, or placebo). Here, n (number analyzed) signifies participants evaluated at specified timepoints.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to 14 days post-vaccination 1 on Day 1 (Day 1 up to Day 15) and up to 14 days post-vaccination 2 on Day 30 (Day 30 up to Day 44)","groups":[{"id":"OG000","title":"CoAd","description":"Participants received a single blinded intramuscular injection of 176 micrograms (mcg) polysaccharide per milliliter (PS/mL) ExPEC9V vaccine in one arm and an unblinded High-dose (HD) quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by a blinded placebo matching the ExPEC9V vaccine on Day 30 in Coadministration (CoAd) group."},{"id":"OG001","title":"Control","description":"Participants received a single blinded intramuscular injection of placebo matching the ExPEC9V vaccine in one arm and an unblinded HD quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by blinded single intramuscular injection of 176 mcg PS/mL ExPEC9V vaccine on Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"476"},{"groupId":"OG001","value":"481"}]}],"classes":[{"title":"Post-vaccination 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"476"},{"groupId":"OG001","value":"481"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.9"},{"groupId":"OG001","value":"54.3"}]}]},{"title":"Post-vaccination 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"461"},{"groupId":"OG001","value":"466"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.9"},{"groupId":"OG001","value":"35.2"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Solicited Systemic AEs for 14 Days After Each Vaccination","description":"An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccination. Solicited systemic AEs were used to assess the reactogenicity of the study vaccine and were pre-defined systemic events for which participants were to be specifically questioned and which were noted by participants in their participant diary for 14 days post vaccination (day of vaccination and the subsequent 14 days). Solicited systemic AEs included fever (body temperature \\>=100.4 degree Fahrenheit), fatigue, headache, nausea, myalgia, and fever.","populationDescription":"FAS included all participants who received at least one study vaccination, regardless of the occurrence of protocol deviations and vaccine type (HD quadrivalent seasonal influenza vaccine, ExPEC9V, or placebo). Here, n (number analyzed) signifies participants evaluated at specified timepoints.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to 14 days post-vaccination 1 on Day 1 (Day 1 up to Day 15) and up to 14 days post-vaccination 2 on Day 30 (Day 30 up to Day 44)","groups":[{"id":"OG000","title":"CoAd","description":"Participants received a single blinded intramuscular injection of 176 micrograms (mcg) polysaccharide per milliliter (PS/mL) ExPEC9V vaccine in one arm and an unblinded High-dose (HD) quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by a blinded placebo matching the ExPEC9V vaccine on Day 30 in Coadministration (CoAd) group."},{"id":"OG001","title":"Control","description":"Participants received a single blinded intramuscular injection of placebo matching the ExPEC9V vaccine in one arm and an unblinded HD quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by blinded single intramuscular injection of 176 mcg PS/mL ExPEC9V vaccine on Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"476"},{"groupId":"OG001","value":"481"}]}],"classes":[{"title":"Post-vaccination 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"476"},{"groupId":"OG001","value":"481"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"53.8"},{"groupId":"OG001","value":"44.9"}]}]},{"title":"Post-vaccination 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"461"},{"groupId":"OG001","value":"466"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.0"},{"groupId":"OG001","value":"36.9"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Unsolicited AEs for 29 Days After Each Vaccination","description":"Percentage of participants with unsolicited AEs for 29 days after each vaccination was reported. An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccination. Unsolicited AEs were all AEs for which the participant was not specifically questioned in the participant diary.","populationDescription":"FAS included all participants who received at least one study vaccination, regardless of the occurrence of protocol deviations and vaccine type (HD quadrivalent seasonal influenza vaccine, ExPEC9V, or placebo). Here, n (number analyzed) signifies participants evaluated at specified timepoints.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to 29 days post-vaccination 1 on Day 1 (Day 1 up to Day 30) and up to 29 days post-vaccination 2 on Day 30 (Day 30 up to Day 59)","groups":[{"id":"OG000","title":"CoAd","description":"Participants received a single blinded intramuscular injection of 176 micrograms (mcg) polysaccharide per milliliter (PS/mL) ExPEC9V vaccine in one arm and an unblinded High-dose (HD) quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by a blinded placebo matching the ExPEC9V vaccine on Day 30 in Coadministration (CoAd) group."},{"id":"OG001","title":"Control","description":"Participants received a single blinded intramuscular injection of placebo matching the ExPEC9V vaccine in one arm and an unblinded HD quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by blinded single intramuscular injection of 176 mcg PS/mL ExPEC9V vaccine on Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"476"},{"groupId":"OG001","value":"481"}]}],"classes":[{"title":"Post-vaccination 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"476"},{"groupId":"OG001","value":"481"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.3"},{"groupId":"OG001","value":"17.7"}]}]},{"title":"Post-vaccination 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"461"},{"groupId":"OG001","value":"466"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.4"},{"groupId":"OG001","value":"15.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Medically-attended Adverse Events (MAAEs) From Vaccination 1 Until 6 Months After Vaccination 2","description":"MAAEs were defined as AEs with medically-attended visits including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason. An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccination.","populationDescription":"FAS included all participants who received at least one study vaccination, regardless of the occurrence of protocol deviations and vaccine type (HD quadrivalent seasonal influenza vaccine, ExPEC9V, or placebo).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"From vaccination 1 on Day 1 up to 6 months after vaccination 2 on Day 30 (up to Day 210)","groups":[{"id":"OG000","title":"CoAd","description":"Participants received a single blinded intramuscular injection of 176 micrograms (mcg) polysaccharide per milliliter (PS/mL) ExPEC9V vaccine in one arm and an unblinded High-dose (HD) quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by a blinded placebo matching the ExPEC9V vaccine on Day 30 in Coadministration (CoAd) group."},{"id":"OG001","title":"Control","description":"Participants received a single blinded intramuscular injection of placebo matching the ExPEC9V vaccine in one arm and an unblinded HD quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by blinded single intramuscular injection of 176 mcg PS/mL ExPEC9V vaccine on Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"476"},{"groupId":"OG001","value":"481"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.2"},{"groupId":"OG001","value":"17.7"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Serious Adverse Events (SAEs) From Vaccination 1 Until 6 Months After Vaccination 2","description":"Percentage of participants with SAEs from vaccination 1 to until 6 months after vaccination 2 was reported. An AE was any untoward medical occurrence in a clinical study administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccine. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.","populationDescription":"FAS included all participants who received at least one study vaccination, regardless of the occurrence of protocol deviations and vaccine type (HD quadrivalent seasonal influenza vaccine, ExPEC9V, or placebo).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"From vaccination 1 on Day 1 up to 6 months after vaccination 2 on Day 30 (up to Day 210)","groups":[{"id":"OG000","title":"CoAd","description":"Participants received a single blinded intramuscular injection of 176 micrograms (mcg) polysaccharide per milliliter (PS/mL) ExPEC9V vaccine in one arm and an unblinded High-dose (HD) quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by a blinded placebo matching the ExPEC9V vaccine on Day 30 in Coadministration (CoAd) group."},{"id":"OG001","title":"Control","description":"Participants received a single blinded intramuscular injection of placebo matching the ExPEC9V vaccine in one arm and an unblinded HD quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by blinded single intramuscular injection of 176 mcg PS/mL ExPEC9V vaccine on Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"476"},{"groupId":"OG001","value":"481"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7"},{"groupId":"OG001","value":"2.3"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers of O-serotype Antigens and EPA as Determined by Multiplex ECL-based Immunoassay","description":"Antibody titers to vaccine O-serotype antigens (O1A, O2, O4, O6A, O15, O16, O18A, O25B, and O75) and EPA as determined by multiplex ECL-based immunoassay were reported.","populationDescription":"PPEI analysis set: who received ExPEC9V with HD quadrivalent seasonal influenza vaccine (CoAd) and ExPEC9V alone (control), with O-antigen immunogenicity data available for atleast one E. coli serotype. N (Overall number of participants analyzed): participants evaluable for this OM, n (number analyzed): participants analyzed at specified timepoints. n=0: data was not planned to be collected and analyzed for Control group at Day 1 as participants did not receive ExPEC9V vaccine on Day 1.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"CoAd Group: Day 1 (Day of ExPEC9V vaccination), Day 30 (29 days after ExPEC9V vaccination), Day 59 (58 days after ExPEC9V vaccination); Control Group: Day 30 (Day of ExPEC9V vaccination), Day 59 (29 days after ExPEC9V vaccination)","groups":[{"id":"OG000","title":"CoAd","description":"Participants received a single blinded intramuscular injection of 176 micrograms (mcg) polysaccharide per milliliter (PS/mL) ExPEC9V vaccine in one arm and an unblinded High-dose (HD) quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by a blinded placebo matching the ExPEC9V vaccine on Day 30 in Coadministration (CoAd) group."},{"id":"OG001","title":"Control","description":"Participants received a single blinded intramuscular injection of placebo matching the ExPEC9V vaccine in one arm and an unblinded HD quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by blinded single intramuscular injection of 176 mcg PS/mL ExPEC9V vaccine on Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"466"},{"groupId":"OG001","value":"464"}]}],"classes":[{"title":"Study Day 1: Serotype: O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"466"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"739070.3","lowerLimit":"669135.0","upperLimit":"816315.0"}]}]},{"title":"Study Day 30: Serotype: O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"448"},{"groupId":"OG001","value":"464"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5317596.0","lowerLimit":"4646244.8","upperLimit":"6085953.1"},{"groupId":"OG001","value":"670938.4","lowerLimit":"608664.5","upperLimit":"739583.8"}]}]},{"title":"Study Day 59: Serotype: O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"438"},{"groupId":"OG001","value":"442"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5075672.7","lowerLimit":"4449521.2","upperLimit":"5789938.3"},{"groupId":"OG001","value":"7240450.4","lowerLimit":"6377170.4","upperLimit":"8220592.9"}]}]},{"title":"Study Day 1: Serotype: O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"466"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"154948.9","lowerLimit":"138739.5","upperLimit":"173052.1"}]}]},{"title":"Study Day 30: Serotype: O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"448"},{"groupId":"OG001","value":"464"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2329847.8","lowerLimit":"2019334.8","upperLimit":"2688108.5"},{"groupId":"OG001","value":"164346.0","lowerLimit":"146920.4","upperLimit":"183838.3"}]}]},{"title":"Study Day 59: Serotype: O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"438"},{"groupId":"OG001","value":"442"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2217716.1","lowerLimit":"1924806.1","upperLimit":"2555200.0"},{"groupId":"OG001","value":"3686001.2","lowerLimit":"3202636.3","upperLimit":"4242319.2"}]}]},{"title":"Study Day 1: Serotype: O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"466"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1564005.0","lowerLimit":"1425279.8","upperLimit":"1716232.6"}]}]},{"title":"Study Day 30: Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"448"},{"groupId":"OG001","value":"464"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5099824.4","lowerLimit":"4537696.2","upperLimit":"5731588.9"},{"groupId":"OG001","value":"1346800.0","lowerLimit":"1239440.7","upperLimit":"1463458.7"}]}]},{"title":"Study Day 59: Serotype: O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"438"},{"groupId":"OG001","value":"442"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5004607.3","lowerLimit":"4462459.9","upperLimit":"5612620.5"},{"groupId":"OG001","value":"6521007.1","lowerLimit":"5808494.1","upperLimit":"7320922.1"}]}]},{"title":"Study Day 1: Serotype: O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"466"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1901934.2","lowerLimit":"1732938.4","upperLimit":"2087410.5"}]}]},{"title":"Study Day 30: Serotype: O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"448"},{"groupId":"OG001","value":"464"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7156596.9","lowerLimit":"6427055.1","upperLimit":"7968949.7"},{"groupId":"OG001","value":"1791162.7","lowerLimit":"1633927.6","upperLimit":"1963528.8"}]}]},{"title":"Study Day 59: Serotype: O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"438"},{"groupId":"OG001","value":"442"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6886171.6","lowerLimit":"6192370.5","upperLimit":"7657707.0"},{"groupId":"OG001","value":"9878642.6","lowerLimit":"8786488.6","upperLimit":"11106550.5"}]}]},{"title":"Study Day 1: Serotype: O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"466"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"741905.9","lowerLimit":"679551.3","upperLimit":"809982.1"}]}]},{"title":"Study Day 30: Serotype: O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"448"},{"groupId":"OG001","value":"464"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3411803.8","lowerLimit":"3028416.3","upperLimit":"3843726.8"},{"groupId":"OG001","value":"699571.2","lowerLimit":"642187.1","upperLimit":"762083.0"}]}]},{"title":"Study Day 59: Serotype: O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"438"},{"groupId":"OG001","value":"442"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3118988.3","lowerLimit":"2776994.8","upperLimit":"3503099.2"},{"groupId":"OG001","value":"4440509.8","lowerLimit":"3939850.4","upperLimit":"5004790.8"}]}]},{"title":"Study Day 1: Serotype O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"466"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1010837.1","lowerLimit":"926671.6","upperLimit":"1102646.9"}]}]},{"title":"Study Day 30: Serotype: O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"448"},{"groupId":"OG001","value":"464"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5893902.4","lowerLimit":"5218770.4","upperLimit":"6656373.5"},{"groupId":"OG001","value":"901580.8","lowerLimit":"824373.8","upperLimit":"986018.6"}]}]},{"title":"Study Day 59: Serotype: O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"438"},{"groupId":"OG001","value":"442"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5713728.3","lowerLimit":"5062282.9","upperLimit":"6449005.6"},{"groupId":"OG001","value":"7743888.3","lowerLimit":"6823177.2","upperLimit":"8788839.0"}]}]},{"title":"Study Day 1: Serotype: O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"466"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4082083.1","lowerLimit":"3777876.0","upperLimit":"4410786.0"}]}]},{"title":"Study Day 30: Serotype: O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"448"},{"groupId":"OG001","value":"464"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22020363.1","lowerLimit":"19671755.8","upperLimit":"24649370.1"},{"groupId":"OG001","value":"3746407.0","lowerLimit":"3461334.1","upperLimit":"4054958.3"}]}]},{"title":"Study Day 59: Serotype: O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"438"},{"groupId":"OG001","value":"442"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20585891.2","lowerLimit":"18468648.5","upperLimit":"22945854.2"},{"groupId":"OG001","value":"28537804.5","lowerLimit":"25492351.3","upperLimit":"31947083.9"}]}]},{"title":"Study Day 1: Serotype: O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"466"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1698792.6","lowerLimit":"1537019.5","upperLimit":"1877592.6"}]}]},{"title":"Study Day 30: Serotype: O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"448"},{"groupId":"OG001","value":"464"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11509271.3","lowerLimit":"10075621.4","upperLimit":"13146913.9"},{"groupId":"OG001","value":"1748932.5","lowerLimit":"1575803.2","upperLimit":"1941083.2"}]}]},{"title":"Study Day 59: Serotype: O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"438"},{"groupId":"OG001","value":"442"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10336834.3","lowerLimit":"9059429.3","upperLimit":"11794357.0"},{"groupId":"OG001","value":"17258900.2","lowerLimit":"14951682.1","upperLimit":"19922148.9"}]}]},{"title":"Study Day 1: Serotype: O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"466"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3418906.1","lowerLimit":"3135488.7","upperLimit":"3727941.6"}]}]},{"title":"Study Day 30: Serotype: O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"448"},{"groupId":"OG001","value":"464"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10802399.4","lowerLimit":"9624671.7","upperLimit":"12124240.3"},{"groupId":"OG001","value":"3215214.2","lowerLimit":"2939502.0","upperLimit":"3516787.0"}]}]},{"title":"Study Day 59: Serotype: O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"438"},{"groupId":"OG001","value":"442"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10254160.6","lowerLimit":"9186950.8","upperLimit":"11445343.8"},{"groupId":"OG001","value":"12407457.8","lowerLimit":"11112490.8","upperLimit":"13853330.5"}]}]},{"title":"Study Day 1: Antigen EPA","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"466"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28443.3","lowerLimit":"24417.0","upperLimit":"33133.4"}]}]},{"title":"Study Day 30: Antigen EPA","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"448"},{"groupId":"OG001","value":"464"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"453328.0","lowerLimit":"367274.7","upperLimit":"559543.7"},{"groupId":"OG001","value":"29136.4","lowerLimit":"24905.8","upperLimit":"34085.6"}]}]},{"title":"Study Day 59: Antigen EPA","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"438"},{"groupId":"OG001","value":"442"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"375153.2","lowerLimit":"307300.5","upperLimit":"457988.0"},{"groupId":"OG001","value":"519757.9","lowerLimit":"426230.4","upperLimit":"633808.2"}]}]}]},{"type":"SECONDARY","title":"CoAd Group: Opsonophagocytic Geometric Mean Titers of O-serotype Antigens as Determined by Multiplex Opsonophagocytic Killing Assay (MOPA)","description":"Opsonophagocytic antibody titers to vaccine O-serotype antigens O1A, O2, O4, O6A, O15, O16, O18A, O25B, and O75 as determined by MOPA were reported.","populationDescription":"PPEI analysis set included all randomized participants who received ExPEC9V in combination with a HD quadrivalent seasonal influenza vaccine for the CoAd group and ExPEC9V alone for the control group and for whom O-antigen immunogenicity data were available for at least one E. coli serotype. Here, N (Overall number of participants analyzed) signifies participants evaluable for this outcome measure and n (number analyzed) signifies participants evaluated for specified categories.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"29 days after the administration of ExPEC9V vaccine on Day 1 (Day 30)","groups":[{"id":"OG000","title":"CoAd","description":"Participants received a single blinded intramuscular injection of 176 micrograms (mcg) polysaccharide per milliliter (PS/mL) ExPEC9V vaccine in one arm and an unblinded High-dose (HD) quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by a blinded placebo matching the ExPEC9V vaccine on Day 30 in Coadministration (CoAd) group."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"448"}]}],"classes":[{"title":"Serotype: O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"448"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1630.0","lowerLimit":"1403.7","upperLimit":"1892.7"}]}]},{"title":"Serotype: O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"448"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2245.4","lowerLimit":"1928.8","upperLimit":"2614.0"}]}]},{"title":"Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"448"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"394.8","lowerLimit":"352.6","upperLimit":"442.0"}]}]},{"title":"Serotype: O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"448"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1078.1","lowerLimit":"949.7","upperLimit":"1223.8"}]}]},{"title":"Serotype: O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"441"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1262.7","lowerLimit":"1103.6","upperLimit":"1444.8"}]}]},{"title":"Serotype: O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"439"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1079.1","lowerLimit":"924.3","upperLimit":"1259.7"}]}]},{"title":"Serotype: O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"424"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"619.0","lowerLimit":"545.7","upperLimit":"702.0"}]}]},{"title":"Serotype: O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"448"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"129.3","lowerLimit":"114.4","upperLimit":"146.0"}]}]},{"title":"Serotype: O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"418"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"92.3","lowerLimit":"79.8","upperLimit":"106.9"}]}]}]},{"type":"SECONDARY","title":"Control Group: Opsonophagocytic Geometric Mean Titers of O-serotype Antigens as Determined by Multiplex Opsonophagocytic Killing Assay (MOPA)","description":"Opsonophagocytic antibody titers to vaccine O-serotype antigens (O1A, O2, O4, O6A, O15, O16, O18A, O25B, and O75) as determined by MOPA were reported.","populationDescription":"PPEI analysis set included all randomized participants who received ExPEC9V in combination with a HD quadrivalent seasonal influenza vaccine for the CoAd group and ExPEC9V alone for the control group and for whom O-antigen immunogenicity data were available for at least one E. coli serotype. Here, N (Overall number of participants analyzed) signifies participants evaluable for this outcome measure and n (number analyzed) signifies participants evaluated for specified categories.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"29 days after the administration of ExPEC9V vaccine on Day 30 (Day 59)","groups":[{"id":"OG000","title":"Control","description":"Participants received a single blinded intramuscular injection of placebo matching the ExPEC9V vaccine in one arm and an unblinded HD quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by blinded single intramuscular injection of 176 mcg PS/mL ExPEC9V vaccine on Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"442"}]}],"classes":[{"title":"Serotype: O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"442"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2149.3","lowerLimit":"1857.2","upperLimit":"2487.3"}]}]},{"title":"Serotype: O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"441"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3459.4","lowerLimit":"2931.0","upperLimit":"4083.1"}]}]},{"title":"Serotype: O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"442"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"482.9","lowerLimit":"423.9","upperLimit":"550.1"}]}]},{"title":"Serotype: O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"442"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1223.2","lowerLimit":"1061.4","upperLimit":"1409.6"}]}]},{"title":"Serotype: O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"372"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1712.4","lowerLimit":"1478.3","upperLimit":"1983.5"}]}]},{"title":"Serotype: O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"441"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1744.7","lowerLimit":"1481.8","upperLimit":"2054.2"}]}]},{"title":"Serotype: O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"277"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1033.5","lowerLimit":"892.9","upperLimit":"1196.3"}]}]},{"title":"Serotype: O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"440"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"177.2","lowerLimit":"153.4","upperLimit":"204.8"}]}]},{"title":"Serotype: O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"336"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"160.0","lowerLimit":"136.7","upperLimit":"187.3"}]}]}]},{"type":"SECONDARY","title":"CoAd Group: Antibody Titers to Vaccine O-serotype Antigens in Participants With and Without History of Urinary Tract Infection (UTI) at Enrollment as Determined by Multiplex ECL-based Immunoassay","description":"Antibody titers to vaccine O-serotype antigens (O1A, O2, O4, O6A, O15, O16, O18A, O25B, and O75) in participants with and without history of UTI at enrollment as determined by multiplex ECL-based immunoassay were reported.","populationDescription":"Analysis population included participants with and without history of UTI at enrollment. Here, N (Overall number of participants analyzed) signifies participants evaluable for this OM and n (number analyzed) signifies participants evaluated for specified categories.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"29 days after the administration of ExPEC9V on Day 1 (Day 30)","groups":[{"id":"OG000","title":"CoAd","description":"Participants received a single blinded intramuscular injection of 176 micrograms (mcg) polysaccharide per milliliter (PS/mL) ExPEC9V vaccine in one arm and an unblinded High-dose (HD) quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by a blinded placebo matching the ExPEC9V vaccine on Day 30 in Coadministration (CoAd) group."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"448"}]}],"classes":[{"title":"UTI at baseline: Serotype O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6160478.9","lowerLimit":"4774254.0","upperLimit":"7949200.1"}]}]},{"title":"No UTI at baseline: Serotype O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"339"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5071887.4","lowerLimit":"4327266.3","upperLimit":"5944640.4"}]}]},{"title":"UTI at baseline: Serotype O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2997612.3","lowerLimit":"2188289.3","upperLimit":"4106257.6"}]}]},{"title":"No UTI at baseline: Serotype O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"339"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2148504.9","lowerLimit":"1831461.7","upperLimit":"2520431.2"}]}]},{"title":"UTI at baseline: Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6432286.8","lowerLimit":"5039834.4","upperLimit":"8209458.8"}]}]},{"title":"No UTI at baseline: Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"339"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4733052.6","lowerLimit":"4145078.6","upperLimit":"5404430.0"}]}]},{"title":"UTI at baseline: Serotype O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8346692.5","lowerLimit":"6553684.5","upperLimit":"10630245.5"}]}]},{"title":"No UTI at baseline: Serotype O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"339"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6811230.2","lowerLimit":"6045896.6","upperLimit":"7673445.4"}]}]},{"title":"UTI at baseline: Serotype O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3960546.9","lowerLimit":"3079674.6","upperLimit":"5093373.0"}]}]},{"title":"No UTI at baseline: Serotype O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"339"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3252055.4","lowerLimit":"2839890.8","upperLimit":"3724039.1"}]}]},{"title":"UTI at baseline: Serotype O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7395994.7","lowerLimit":"5815386.0","upperLimit":"9406209.2"}]}]},{"title":"No UTI at baseline: Serotype O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"339"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5479005.5","lowerLimit":"4759609.9","upperLimit":"6307134.7"}]}]},{"title":"UTI at baseline: Serotype O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24137685.4","lowerLimit":"19023324.3","upperLimit":"30627026.5"}]}]},{"title":"No UTI at baseline: Serotype O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"339"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21379844.8","lowerLimit":"18803127.4","upperLimit":"24309667.0"}]}]},{"title":"UTI at baseline: Serotype O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16547661.1","lowerLimit":"12619680.5","upperLimit":"21698258.2"}]}]},{"title":"No UTI at baseline: Serotype O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"339"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10241074.7","lowerLimit":"8802458.2","upperLimit":"11914809.4"}]}]},{"title":"UTI at baseline: Serotype O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12800664.6","lowerLimit":"9939927.9","upperLimit":"16484728.5"}]}]},{"title":"No UTI at baseline: Serotype O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"339"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10228671.4","lowerLimit":"8988055.3","upperLimit":"11640529.1"}]}]}]},{"type":"SECONDARY","title":"Control Group: Antibody Titers to Vaccine O-serotype Antigens in Participants With and Without History of UTI at Enrollment as Determined by Multiplex ECL-based Immunoassay","description":"Antibody titers to vaccine O-serotype antigens (O1A, O2, O4, O6A, O15, O16, O18A, O25B, and O75) in participants with and without history of UTI at enrollment as determined by multiplex ECL-based immunoassay were reported.","populationDescription":"Analysis population included participants with and without history of UTI at enrollment. Here, N (Overall number of participants analyzed) signifies participants evaluable for this OM and n (number analyzed) signifies participants evaluated for specified categories.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"29 days after the administration of ExPEC9V on Day 30 (Day 59)","groups":[{"id":"OG000","title":"Control","description":"Participants received a single blinded intramuscular injection of placebo matching the ExPEC9V vaccine in one arm and an unblinded HD quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by blinded single intramuscular injection of 176 mcg PS/mL ExPEC9V vaccine on Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"442"}]}],"classes":[{"title":"UTI at baseline: Serotype O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8651535.9","lowerLimit":"6830776.3","upperLimit":"10957623.4"}]}]},{"title":"No UTI at baseline: Serotype O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"328"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6805961.9","lowerLimit":"5856748.1","upperLimit":"7909016.4"}]}]},{"title":"UTI at baseline: Serotype O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4943585.5","lowerLimit":"3847110.9","upperLimit":"6352569.0"}]}]},{"title":"No UTI at baseline: Serotype O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"328"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3328481.3","lowerLimit":"2815169.6","upperLimit":"3935389.1"}]}]},{"title":"UTI at baseline: Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6839103.3","lowerLimit":"5512300.2","upperLimit":"8485266.0"}]}]},{"title":"No UTI at baseline: Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"328"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6413949.7","lowerLimit":"5590982.3","upperLimit":"7358054.2"}]}]},{"title":"UTI at baseline: Serotype O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12562209.1","lowerLimit":"9936839.7","upperLimit":"15881215.9"}]}]},{"title":"No UTI at baseline: Serotype O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"328"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9087046.9","lowerLimit":"7941272.3","upperLimit":"10398135.1"}]}]},{"title":"UTI at baseline: Serotype O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5243066.0","lowerLimit":"4122485.6","upperLimit":"6668244.4"}]}]},{"title":"No UTI at baseline: Serotype O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"328"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4191364.6","lowerLimit":"3650913.9","upperLimit":"4811819.1"}]}]},{"title":"UTI at baseline: Serotype O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7315224.0","lowerLimit":"5814557.3","upperLimit":"9203194.7"}]}]},{"title":"No UTI at baseline: Serotype O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"328"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7898684.5","lowerLimit":"6789138.0","upperLimit":"9189563.8"}]}]},{"title":"UTI at baseline: Serotype O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31863829.0","lowerLimit":"25896033.0","upperLimit":"39206916.3"}]}]},{"title":"No UTI at baseline: Serotype O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"328"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27465040.3","lowerLimit":"24014129.8","upperLimit":"31411858.3"}]}]},{"title":"UTI at baseline: Serotype O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18356720.0","lowerLimit":"14010182.8","upperLimit":"24051732.6"}]}]},{"title":"No UTI at baseline: Serotype O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"328"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16892921.0","lowerLimit":"14254902.0","upperLimit":"20019133.1"}]}]},{"title":"UTI at baseline: Serotype O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14476793.4","lowerLimit":"11780693.2","upperLimit":"17789916.6"}]}]},{"title":"No UTI at baseline: Serotype O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"328"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11759797.5","lowerLimit":"10323754.0","upperLimit":"13395596.0"}]}]}]},{"type":"SECONDARY","title":"CoAd Group: Opsonophagocytic Antibody Titers to Vaccine O-serotype Antigens in Participants With and Without History of UTI at Enrollment as Determined by Multiplex Opsonophagocytic Killing Assay (MOPA)","description":"Opsonophagocytic antibody titers to vaccine O-serotype antigens (O1A, O2, O4, O6A, O15, O16, O18A, O25B, and O75) in participants with and without history of UTI at enrollment as determined by MOPA were reported.","populationDescription":"Analysis population included participants with and without history of UTI at enrollment. Here, N (Overall number of participants analyzed) signifies participants evaluable for this OM and n (number analyzed) signifies participants evaluated for specified categories.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"29 days after the administration of ExPEC9V on Day 1 (Day 30)","groups":[{"id":"OG000","title":"CoAd","description":"Participants received a single blinded intramuscular injection of 176 micrograms (mcg) polysaccharide per milliliter (PS/mL) ExPEC9V vaccine in one arm and an unblinded High-dose (HD) quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by a blinded placebo matching the ExPEC9V vaccine on Day 30 in Coadministration (CoAd) group."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"448"}]}],"classes":[{"title":"UTI at baseline: Serotype O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1960.7","lowerLimit":"1476.2","upperLimit":"2604.4"}]}]},{"title":"No UTI at baseline: Serotype O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"339"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1535.9","lowerLimit":"1288.8","upperLimit":"1830.5"}]}]},{"title":"UTI at baseline: Serotype O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2609.3","lowerLimit":"1890.7","upperLimit":"3600.8"}]}]},{"title":"No UTI at baseline: Serotype O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"339"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2139.6","lowerLimit":"1800.2","upperLimit":"2543.0"}]}]},{"title":"UTI at baseline: Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"455.3","lowerLimit":"352.5","upperLimit":"588.0"}]}]},{"title":"No UTI at baseline: Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"339"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"377.1","lowerLimit":"332.8","upperLimit":"427.3"}]}]},{"title":"UTI at baseline: Serotype O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1279.6","lowerLimit":"947.0","upperLimit":"1729.2"}]}]},{"title":"No UTI at baseline: Serotype O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"339"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1020.3","lowerLimit":"889.4","upperLimit":"1170.4"}]}]},{"title":"UTI at baseline: Serotype O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1492.2","lowerLimit":"1130.9","upperLimit":"1969.0"}]}]},{"title":"No UTI at baseline: Serotype O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"333"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1196.2","lowerLimit":"1025.0","upperLimit":"1395.9"}]}]},{"title":"UTI at baseline: Serotype O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1585.8","lowerLimit":"1180.3","upperLimit":"2130.7"}]}]},{"title":"No UTI at baseline: Serotype O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"331"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"951.7","lowerLimit":"794.9","upperLimit":"1139.5"}]}]},{"title":"UTI at baseline: Serotype O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"619.3","lowerLimit":"481.5","upperLimit":"796.6"}]}]},{"title":"No UTI at baseline: Serotype O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"321"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"618.9","lowerLimit":"534.7","upperLimit":"716.3"}]}]},{"title":"UTI at baseline: Serotype O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"175.1","lowerLimit":"133.0","upperLimit":"230.6"}]}]},{"title":"No UTI at baseline: Serotype O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"339"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"117.3","lowerLimit":"102.6","upperLimit":"134.1"}]}]},{"title":"UTI at baseline: Serotype O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"104.1","lowerLimit":"77.7","upperLimit":"139.5"}]}]},{"title":"No UTI at baseline: Serotype O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"318"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","lowerLimit":"75.1","upperLimit":"105.3"}]}]}]},{"type":"SECONDARY","title":"Control Group: Opsonophagocytic Antibody Titers to Vaccine O-serotype Antigens in Participants With and Without History of UTI at Enrollment as Determined by Multiplex Opsonophagocytic Killing Assay (MOPA)","description":"Opsonophagocytic antibody titers to vaccine O-serotype antigens (O1A, O2, O4, O6A, O15, O16, O18A, O25B, and O75) in participants with and without history of UTI at enrollment as determined by MOPA were reported.","populationDescription":"Analysis population included participants with and without history of UTI at enrollment. Here, N (Overall number of participants analyzed) signifies participants evaluable for this OM and n (number analyzed) signifies participants evaluated for specified categories.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"29 days after the administration of ExPEC9V on Day 30 (Day 59)","groups":[{"id":"OG000","title":"Control","description":"Participants received a single blinded intramuscular injection of placebo matching the ExPEC9V vaccine in one arm and an unblinded HD quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1, followed by blinded single intramuscular injection of 176 mcg PS/mL ExPEC9V vaccine on Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"442"}]}],"classes":[{"title":"UTI at baseline: Serotype O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2286.3","lowerLimit":"1709.8","upperLimit":"3057.3"}]}]},{"title":"No UTI at baseline: Serotype O1A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"328"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2103.6","lowerLimit":"1775.1","upperLimit":"2492.9"}]}]},{"title":"UTI at baseline: Serotype O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3910.8","lowerLimit":"2842.1","upperLimit":"5381.4"}]}]},{"title":"No UTI at baseline: Serotype O2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"327"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3314.6","lowerLimit":"2728.4","upperLimit":"4026.9"}]}]},{"title":"UTI at baseline: Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"450.4","lowerLimit":"352.6","upperLimit":"575.3"}]}]},{"title":"No UTI at baseline: Serotype O4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"328"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"494.7","lowerLimit":"424.0","upperLimit":"577.2"}]}]},{"title":"UTI at baseline: Serotype O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1584.5","lowerLimit":"1190.0","upperLimit":"2109.8"}]}]},{"title":"No UTI at baseline: Serotype O6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"328"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1117.9","lowerLimit":"949.8","upperLimit":"1315.8"}]}]},{"title":"UTI at baseline: Serotype O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2019.4","lowerLimit":"1490.7","upperLimit":"2735.5"}]}]},{"title":"No UTI at baseline: Serotype O15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"274"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1614.3","lowerLimit":"1364.6","upperLimit":"1909.7"}]}]},{"title":"UTI at baseline: Serotype O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1562.4","lowerLimit":"1150.8","upperLimit":"2121.1"}]}]},{"title":"No UTI at baseline: Serotype O16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"327"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1813.1","lowerLimit":"1494.1","upperLimit":"2200.2"}]}]},{"title":"UTI at baseline: Serotype O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"74"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1282.5","lowerLimit":"977.7","upperLimit":"1682.3"}]}]},{"title":"No UTI at baseline: Serotype O18A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"203"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"955.3","lowerLimit":"803.2","upperLimit":"1136.3"}]}]},{"title":"UTI at baseline: Serotype O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"113"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"187.1","lowerLimit":"137.9","upperLimit":"253.8"}]}]},{"title":"No UTI at baseline: Serotype O25B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"327"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"173.9","lowerLimit":"147.6","upperLimit":"205.0"}]}]},{"title":"UTI at baseline: Serotype O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"179.9","lowerLimit":"134.1","upperLimit":"241.5"}]}]},{"title":"No UTI at baseline: Serotype O75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"252"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"153.9","lowerLimit":"127.7","upperLimit":"185.5"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"1","timeFrame":"All-Cause Mortality: CoAd/control group post dose-1:Day 1 to Day 30, CoAd/control group post dose-2:Day 30 to Day 210; SAEs: CoAd/control group post dose-1: Day 1 to Day 30, CoAd/control group post dose-2:Day 30 to Day 210; Unsolicited AEs (other AEs): Up to 29 days post-dose 1 (Day 1 to Day 30), Up to 29 days post-dose 2 (Day 30 to Day 59); Solicited local and systemic AEs: Up to 14 days post-dose 1 (Day 1 to Day 15), Up to 14 days post-dose 2 (Day 30 to Day 44)","description":"Full analysis set included all participants who received at least one study vaccination, regardless of the occurrence of protocol deviations and vaccine type (HD quadrivalent seasonal influenza vaccine, ExPEC9V, or placebo).","eventGroups":[{"id":"EG000","title":"CoAd: Post-dose 1","description":"Participants received a single blinded intramuscular injection of 176 micrograms (mcg) polysaccharide per milliliter (PS/mL) ExPEC9V vaccine in one arm and an unblinded HD quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":476,"seriousNumAffected":0,"seriousNumAtRisk":476,"otherNumAffected":362,"otherNumAtRisk":476},{"id":"EG001","title":"CoAd: Post-dose 2","description":"Participants received a single blinded intramuscular injection of placebo matching the ExPEC9V vaccine on Day 30.","deathsNumAffected":0,"deathsNumAtRisk":461,"seriousNumAffected":13,"seriousNumAtRisk":461,"otherNumAffected":148,"otherNumAtRisk":461},{"id":"EG002","title":"Control: Post-dose 1","description":"Participants received a single blinded intramuscular injection of placebo matching the ExPEC9V vaccine in one arm and an unblinded HD quadrivalent seasonal influenza vaccine (240 mcg of haemagglutinin) in the contralateral arm on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":481,"seriousNumAffected":3,"seriousNumAtRisk":481,"otherNumAffected":326,"otherNumAtRisk":481},{"id":"EG003","title":"Control: Post-dose 2","description":"Participants received a single blinded intramuscular injection of 176 mcg PS/mL ExPEC9V vaccine on Day 30.","deathsNumAffected":2,"deathsNumAtRisk":466,"seriousNumAffected":8,"seriousNumAtRisk":466,"otherNumAffected":225,"otherNumAtRisk":466}],"seriousEvents":[{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":0,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":1,"numAtRisk":466}]},{"term":"Angina Pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":0,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":1,"numAtRisk":466}]},{"term":"Angina Unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":1,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":0,"numAtRisk":466}]},{"term":"Atrial Fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":1,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":0,"numAtRisk":466}]},{"term":"Coronary Artery Disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":1,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":0,"numAtRisk":466}]},{"term":"Goitre","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":1,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":0,"numAtRisk":466}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":0,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":1,"numAtRisk":466}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":0,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":1,"numAtRisk":466}]},{"term":"Melaena","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":1,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":0,"numAtRisk":466}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":1,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":0,"numAtRisk":466}]},{"term":"Small Intestinal Obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":0,"numAtRisk":461},{"groupId":"EG002","numAffected":1,"numAtRisk":481},{"groupId":"EG003","numAffected":1,"numAtRisk":466}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":0,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":1,"numAtRisk":466}]},{"term":"Cholecystitis Acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":1,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":0,"numAtRisk":466}]},{"term":"COVID-19 Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":1,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":0,"numAtRisk":466}]},{"term":"Escherichia Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":1,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":0,"numAtRisk":466}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":1,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":0,"numAtRisk":466}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":0,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":1,"numAtRisk":466}]},{"term":"Pelvic Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":1,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":0,"numAtRisk":466}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":1,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":0,"numAtRisk":466}]},{"term":"Benign Gastric Neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":0,"numAtRisk":461},{"groupId":"EG002","numAffected":1,"numAtRisk":481},{"groupId":"EG003","numAffected":0,"numAtRisk":466}]},{"term":"Pancreatic Carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":1,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":0,"numAtRisk":466}]},{"term":"Prostate Cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":1,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":0,"numAtRisk":466}]},{"term":"Ischaemic Stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":0,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":1,"numAtRisk":466}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":0,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":1,"numAtRisk":466}]},{"term":"Transient Ischaemic Attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":1,"numAtRisk":461},{"groupId":"EG002","numAffected":1,"numAtRisk":481},{"groupId":"EG003","numAffected":0,"numAtRisk":466}]},{"term":"Acute Kidney Injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":1,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":0,"numAtRisk":466}]},{"term":"Urinary Retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":0,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":1,"numAtRisk":466}]},{"term":"Chronic Obstructive Pulmonary Disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":2,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":0,"numAtRisk":466}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":0,"numAtRisk":461},{"groupId":"EG002","numAffected":1,"numAtRisk":481},{"groupId":"EG003","numAffected":0,"numAtRisk":466}]},{"term":"Pulmonary Embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":0,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":1,"numAtRisk":466}]},{"term":"Excessive Skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":476},{"groupId":"EG001","numAffected":0,"numAtRisk":461},{"groupId":"EG002","numAffected":0,"numAtRisk":481},{"groupId":"EG003","numAffected":1,"numAtRisk":466}]}],"otherEvents":[{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":476},{"groupId":"EG001","numAffected":1,"numAtRisk":461},{"groupId":"EG002","numAffected":2,"numAtRisk":481},{"groupId":"EG003","numAffected":0,"numAtRisk":466}]},{"term":"Nausea (Solicited)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":66,"numAtRisk":476},{"groupId":"EG001","numAffected":30,"numAtRisk":461},{"groupId":"EG002","numAffected":38,"numAtRisk":481},{"groupId":"EG003","numAffected":35,"numAtRisk":466}]},{"term":"Fatigue (Solicited)","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":184,"numAtRisk":476},{"groupId":"EG001","numAffected":77,"numAtRisk":461},{"groupId":"EG002","numAffected":135,"numAtRisk":481},{"groupId":"EG003","numAffected":111,"numAtRisk":466}]},{"term":"Pyrexia (Solicited)","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":476},{"groupId":"EG001","numAffected":5,"numAtRisk":461},{"groupId":"EG002","numAffected":11,"numAtRisk":481},{"groupId":"EG003","numAffected":18,"numAtRisk":466}]},{"term":"Vaccination Site Erythema (Solicited)","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":74,"numAtRisk":476},{"groupId":"EG001","numAffected":5,"numAtRisk":461},{"groupId":"EG002","numAffected":32,"numAtRisk":481},{"groupId":"EG003","numAffected":58,"numAtRisk":466}]},{"term":"Vaccination Site Pain (Solicited)","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":304,"numAtRisk":476},{"groupId":"EG001","numAffected":53,"numAtRisk":461},{"groupId":"EG002","numAffected":252,"numAtRisk":481},{"groupId":"EG003","numAffected":160,"numAtRisk":466}]},{"term":"Vaccination Site Swelling (Solicited)","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":65,"numAtRisk":476},{"groupId":"EG001","numAffected":2,"numAtRisk":461},{"groupId":"EG002","numAffected":34,"numAtRisk":481},{"groupId":"EG003","numAffected":47,"numAtRisk":466}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":476},{"groupId":"EG001","numAffected":4,"numAtRisk":461},{"groupId":"EG002","numAffected":9,"numAtRisk":481},{"groupId":"EG003","numAffected":1,"numAtRisk":466}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":476},{"groupId":"EG001","numAffected":10,"numAtRisk":461},{"groupId":"EG002","numAffected":3,"numAtRisk":481},{"groupId":"EG003","numAffected":7,"numAtRisk":466}]},{"term":"Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":476},{"groupId":"EG001","numAffected":5,"numAtRisk":461},{"groupId":"EG002","numAffected":6,"numAtRisk":481},{"groupId":"EG003","numAffected":9,"numAtRisk":466}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":476},{"groupId":"EG001","numAffected":3,"numAtRisk":461},{"groupId":"EG002","numAffected":4,"numAtRisk":481},{"groupId":"EG003","numAffected":4,"numAtRisk":466}]},{"term":"Myalgia (Solicited)","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":154,"numAtRisk":476},{"groupId":"EG001","numAffected":56,"numAtRisk":461},{"groupId":"EG002","numAffected":131,"numAtRisk":481},{"groupId":"EG003","numAffected":105,"numAtRisk":466}]},{"term":"Headache (Solicited)","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":139,"numAtRisk":476},{"groupId":"EG001","numAffected":60,"numAtRisk":461},{"groupId":"EG002","numAffected":119,"numAtRisk":481},{"groupId":"EG003","numAffected":95,"numAtRisk":466}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application."},"pointOfContact":{"title":"Executive Medical Director","organization":"Janssen Research & Development, LLC","email":"ClinicalTrialDisclosure@its.jnj.com","phone":"844-434-4210"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2023-09-22","uploadDate":"2026-02-10T10:46","filename":"Prot_000.pdf","size":2144892},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2024-05-21","uploadDate":"2026-02-10T10:46","filename":"SAP_001.pdf","size":1834674}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2026-03-02","type":"ACTUAL"}}}}},"hasResults":true}